350 related articles for article (PubMed ID: 1701665)
1. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factor.
Logan TF; Virji MA; Gooding WE; Bontempo FA; Ernstoff MS; Kirkwood JM
J Natl Cancer Inst; 1992 Dec; 84(23):1802-10. PubMed ID: 1433370
[TBL] [Abstract][Full Text] [Related]
3. Plasmin generation and fibrin(ogen)olysis following desmopressin infusion.
Takahashi H; Tatewaki W; Wada K; Niwano H; Hanano M; Shibata A
Am J Hematol; 1991 Apr; 36(4):255-8. PubMed ID: 1826408
[TBL] [Abstract][Full Text] [Related]
4. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo.
van Hinsbergh VW; Kooistra T; van den Berg EA; Princen HM; Fiers W; Emeis JJ
Blood; 1988 Nov; 72(5):1467-73. PubMed ID: 3140909
[TBL] [Abstract][Full Text] [Related]
6. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.
Leebeek FW; Kluft C; Knot EA; de Maat MP; Wilson JH
Gastroenterology; 1991 Nov; 101(5):1382-90. PubMed ID: 1718809
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.
Reilly CF; Fujita T; Hutzelmann JE; Mayer EJ; Shebuski RJ
Circulation; 1991 Jul; 84(1):287-92. PubMed ID: 1905594
[TBL] [Abstract][Full Text] [Related]
9. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
Carr ME; Krishnamurti C; Alving BM
Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic response to tumor necrosis factor in healthy subjects.
van der Poll T; Levi M; Büller HR; van Deventer SJ; de Boer JP; Hack CE; ten Cate JW
J Exp Med; 1991 Sep; 174(3):729-32. PubMed ID: 1714936
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
12. Fibrin-specific fibrinolysis.
Collen D; Lijnen HR
Ann N Y Acad Sci; 1992 Dec; 667():259-71. PubMed ID: 1285022
[No Abstract] [Full Text] [Related]
13. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells.
van Hinsbergh VW; van den Berg EA; Fiers W; Dooijewaard G
Blood; 1990 May; 75(10):1991-8. PubMed ID: 2140060
[TBL] [Abstract][Full Text] [Related]
14. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod.
Dempfle CE; Argiriou S; Kucher K; Müller-Peltzer H; Rübsamen K; Heene DL
Blood; 2000 Oct; 96(8):2793-802. PubMed ID: 11023513
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic changes in a patient with toxic shock syndrome; release of active u-PA.
Haj MA; Robbie LA; Croll A; Adey GD; Bennett B
Intensive Care Med; 1998 Mar; 24(3):258-61. PubMed ID: 9565810
[TBL] [Abstract][Full Text] [Related]
16. The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies.
van de Kar NC; van Hinsbergh VW; Brommer EJ; Monnens LA
Pediatr Res; 1994 Aug; 36(2):257-64. PubMed ID: 7970942
[TBL] [Abstract][Full Text] [Related]
17. Time dependent release of tissue-type plasminogen activator and plasminogen activator inhibitor into the circulation of pigs during shock.
Siebeck M; Spannagl M; Hoffmann H; Schramm W; Fritz H
Blood Coagul Fibrinolysis; 1991 Jun; 2(3):459-64. PubMed ID: 1834237
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
Nielsen JD; Gram J; Fabrin K; Holm-Nielsen A; Jespersen J
Br J Urol; 1997 Jul; 80(1):105-10. PubMed ID: 9240188
[TBL] [Abstract][Full Text] [Related]
19. Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells.
van Hinsbergh VW; Kooistra T; Scheffer MA; Hajo van Bockel J; van Muijen GN
Blood; 1990 Apr; 75(7):1490-7. PubMed ID: 2107884
[TBL] [Abstract][Full Text] [Related]
20. Effect of tumor necrosis factor on the human fibrinolytic system.
Silverman P; Goldsmith GH; Spitzer TR; Rehmus EH; Berger NA
J Clin Oncol; 1990 Mar; 8(3):468-75. PubMed ID: 2106575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
